Previous 10 | Next 10 |
Summary Sema4's restructuring plan has a number of potential downsides that could affect the company's cash position in the coming few quarters. The booting of the CEO signals the start of a strategic focus on short-term survival away from long-term growth. Even if management succee...
Summary What started as a seemingly innocuous leadership transition at one of the country's leading molecular diagnostic firms, NeoGenomics, Inc., has evolved into something much more chaotic. After the departure of former NeoGenomics, Inc. CEO and company veteran Douglas VanOort last y...
Start Time: 08:30 End Time: 09:27 SOPHiA GENETICS SA (SOPH) Q3 2022 Earnings Conference Call November 08, 2022, 08:30 AM ET Company Participants Jurgi Camblong - Founder and CEO Ross Muken - CFO Philippe Menu - Chief Medical Officer Jennifer Pottage -...
SOPHiA Genetics press release ( NASDAQ: SOPH ): Q3 Non-GAAP EPS of -$0.30. Revenue of $11.6M (+12.0% Y/Y) beats by $0.15M . Adjusted operating loss for the third quarter of 2022 was $19.3 million, compared to $17.0 million for the third quarter of 2021. "We are...
BOSTON and LAUSANNE, Switzerland, Nov. 08, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today reported financial results for the third quarter ended September 30, 2022. Recent Highlights Revenue for the ...
SOPHiA GENETICS Partners with Microsoft to Accelerate Multimodal Health Data Analysis PR Newswire The agreement is to expand and reinforce data-driven medicine through the SOPHiA DDM™ health data analysis platform available with Microsoft Azure GE...
BOSTON and GENEVA, Switzerland, Oct. 06, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced it will release its financial results for the third quarter of fiscal 2022 before U.S. markets open on Tuesday, Nov...
SOPHiA GENETICS ( NASDAQ: SOPH ) has entered a partnership with precision oncology company Boundless Bio to develop therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers . Boundless Bio is developing the first ecDNA-dir...
Highlights include: a memorandum of understanding with Memorial Sloan Kettering Cancer Center and a novel new partnership with Boundless Bio, a next-generation precision oncology company SOPHiA GENETICS’ next-generation solution CarePath, fueled by current real world obse...
BOSTON and GENEVA, Switzerland, Sept. 20, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, will host its first-ever Investor Day TODAY in-person at PUBLIC Hotel in New York City. The event will begin at 1:30 p.m. EDT and is ex...
News, Short Squeeze, Breakout and More Instantly...
SOPHiA GENETICS Announces L'hôpital Universitaire Avicenne is Live on SOPHiA DDM™ Canada NewsWire The hospital will use the SOPHiA DDM™ Platform to enhance its testing and research of blood cancers BOSTON and ROLLE, Switzerland , July 2...
SOPHIA GENETICS Announces Expanded Relationship with Canada-Based OncoHelix PR Newswire OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS® powered with SOPHiA DDM™ BOSTON and ROLLE, Switzerland , July 24 , 2024 /PRN...
SOPHiA GENETICS Announces Expanded Relationship with Canada-Based OncoHelix PR Newswire OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS ® powered with SOPHiA DDM™ BOSTON and ROLLE, Switzerland , July 24, 2024 /...